Natus Medical (BABY) Receives Daily Coverage Optimism Rating of 0.06

News headlines about Natus Medical (NASDAQ:BABY) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Natus Medical earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 45.9806348678706 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several brokerages have recently weighed in on BABY. Zacks Investment Research raised shares of Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research note on Tuesday, October 24th. BidaskClub downgraded shares of Natus Medical from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $46.50.

Natus Medical (NASDAQ:BABY) opened at $36.40 on Friday. The company has a market cap of $1,110.00, a PE ratio of -606.67 and a beta of 0.84. Natus Medical has a 12 month low of $31.65 and a 12 month high of $43.60. The company has a quick ratio of 3.36, a current ratio of 4.21 and a debt-to-equity ratio of 0.36.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.02. The company had revenue of $122.60 million for the quarter, compared to the consensus estimate of $122.41 million. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The firm’s revenue was up 34.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.39 EPS. analysts forecast that Natus Medical will post 1.74 earnings per share for the current fiscal year.

In related news, Director William M. Moore sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $41.01, for a total value of $205,050.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Dong Chune Christopher Chung sold 12,642 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $42.91, for a total transaction of $542,468.22. Following the completion of the transaction, the vice president now directly owns 141,414 shares in the company, valued at approximately $6,068,074.74. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Insider Buying and Selling by Quarter for Natus Medical (NASDAQ:BABY)

What are top analysts saying about Natus Medical? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Natus Medical and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit